Target intelligence / Profile preview

Fusobacterium nucleatum Fap2 lectin (Fap2)

Target
Fap2
Molecular classification
Lectin, Autotransporter adhesin, Outer membrane protein, Bacterial virulence factor, Type Va autotransporter
01

Overview

Fusobacterium nucleatum Fap2 lectin, also known as Fibroblast activation protein 2, is a large (~390 kDa) outer membrane autotransporter protein that serves as a critical virulence factor for the bacterium (3.1.4, 3.4.1). It functions as a bifunctional adhesin, specifically recognizing and binding to the carbohydrate moiety Gal-GalNAc (D-galactose-β(1-3)-N-acetyl-D-galactosamine), which is overexpressed on the surface of colorectal cancer (CRC) cells and other adenocarcinomas (2.3.1, 2.3.3). This interaction facilitates the 'precision homing' and colonization of F. nucleatum in tumor tissues, where the bacterium promotes tumor progression, metastasis, and chemoresistance (2.3.4, 3.4.3). Additionally, Fap2 interacts with the inhibitory receptor TIGIT on natural killer (NK) cells and T lymphocytes, leading to the suppression of host anti-tumor immunity (2.1.1, 3.1.5). Due to its central role in bacterial recruitment to tumors and immune evasion, Fap2 is considered a promising therapeutic target for the treatment of F. nucleatum-associated cancers, with strategies including the development of inhibitory antibodies, small molecules, and vaccines (3.2.2, 3.3.1).

Other names
Fibroblast activation protein 2Fap2 proteinGal-GalNAc-binding lectinGalactose-inhibitable adhesinFusobacterium autotransporter protein 2
02

Mechanism of action

Fap2 mediates bacterial recruitment to tumors by binding to Gal-GalNAc on cancer cells and inhibits host anti-tumor immunity by activating the TIGIT receptor on NK and T cells (2.1.1, 2.3.1, 3.4.4).

03

Biological functions

AdhesionImmune evasionHemagglutinationCoaggregationCell invasionBiofilm formationBacterial colonization
04

Disease associations

Colorectal cancerBreast cancerPeriodontitisPreterm birthAppendicitisInflammatory bowel diseaseEsophageal cancer
05

Safety considerations

Disruption of the oral microbiome (where F. nucleatum is a commensal)Specificity of targeting (potential off-target binding to healthy tissues expressing Gal-GalNAc)Potential for systemic immune modulationComplexity of the gut microbiome interactions
06

Interacting drugs

GalNAc (N-acetylgalactosamine)

3 more in the full profile.

07

Biomarkers

Gal-GalNAc (Thomsen-Friedenreich antigen) expression levelsFusobacterium nucleatum DNA levels (qPCR/FISH)Fap2 protein expression in tumor biopsiesAnti-Fap2 antibody titers

Beyond the preview

Go deeper on Fusobacterium nucleatum Fap2 lectin (Fap2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fusobacterium nucleatum Fap2 lectin (Fap2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call